Levetiracetam Injection
Product Images NDC 36000-356

11 FDA label images from Baxter Healthcare Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 36000-356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Description (Description)
Chemical structure of levetiracetam. The diagram shows the molecular arrangement of levetiracetam, highlighting the lactam and amide functional groups along with its chiral center.*
FDA Label Image

Figure-01 (Figure 01)

Figure-01 (Figure 01)
A bar graph showing the percentage of patients in three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The percentage of patients is highest for Levetiracetam 3000 mg/day at 39.6%, followed by Levetiracetam 1000 mg/day at 37.1%, and lowest for Placebo at 7.4%. Asterisks indicate statistical significance versus placebo.*
FDA Label Image

Figure-02 (Figure 02)

Figure-02 (Figure 02)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, ranging from 0% to 45%. Percentages shown are 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day, with asterisks marking statistical significance versus placebo.*
FDA Label Image

Figure-03 (Figure 03)

Figure-03 (Figure 03)
A bar chart comparing the percentage of patients experiencing a given outcome in two groups: Placebo (N=104) at 14.4% and Levetiracetam 3000 mg/day (N=180) at 39.4%, with an asterisk indicating statistical significance versus placebo. The y-axis represents percentage of patients from 0% to 45%.*
FDA Label Image

Figure-04 (Figure 04)

Figure-04 (Figure 04)
A vertical bar chart comparing the percentage of patients in placebo and levetiracetam groups. The placebo group (N=84) shows 45.2% of patients, while the levetiracetam group (N=79) shows 72.2%, marked as statistically significant versus placebo.*
FDA Label Image

Bag-5mg-ml (Bag 5mg mL)

Bag-5mg-ml (Bag 5mg mL)
This drug facts panel for Levetiracetam Injection 5 mg/mL in 0.82% Sodium Chloride provides detailed usage instructions for intravenous infusion, specifying each 100 mL contains 500 mg levetiracetam. It includes storage recommendations, cautions against dilution and use of plastic containers, and manufacturer information for Baxter Healthcare Corporation. The label emphasizes single-dose use and disposal of unused portions.*
FDA Label Image

Overwrap-5mg-ml (Overwrap 5mg mL)

Overwrap-5mg-ml (Overwrap 5mg mL)
Levetiracetam 5 mg/mL Injection in 0.82% Sodium Chloride, 500 mg/100 mL (100 mL) single-dose intravenous infusion bag. The label states infusion over 15 minutes and cautions against dilution or use with plastic containers in series. Manufactured for Baxter Healthcare Corporation, made in Ireland.*
FDA Label Image

Bag-10mg-ml (Bag 10mg mL)

Bag-10mg-ml (Bag 10mg mL)
Label for Levetiracetam in 0.75% Sodium Chloride Injection, 1000 mg/100 mL (10 mg/mL) intravenous infusion by Baxter Healthcare Corporation. The label includes dosing instructions, storage conditions, formulation details, and cautions. The product is a 100 mL single-dose bag made in Ireland and intended for human prescription use.*
FDA Label Image

Overwrap-10mg-ml (Overwrap 10mg mL)

Overwrap-10mg-ml (Overwrap 10mg mL)
Label for Levetiracetam Injection in 0.75% Sodium Chloride by Baxter Healthcare Corporation. The product strength is 1000 mg per 100 mL (10 mg/mL) intravenous infusion, single-dose bag. The label includes storage instructions, usage cautions, and manufacturing details, noting it is made in Ireland and intended for intravenous use only.*
FDA Label Image

Bag-15mg-ml (Bag 15mg mL)

Bag-15mg-ml (Bag 15mg mL)
Levetiracetam 1500 mg/100 mL (15 mg/mL) intravenous injection in 0.54% Sodium Chloride by Baxter Healthcare Corporation. The single-dose infusion bag label includes dosing concentration, infusion instructions, storage conditions, and cautions for use. It specifies the product is for intravenous infusion only and not to use plastic containers in series connections.*
FDA Label Image

Overwrap-15mg-ml (Overwrap 15mg mL)

Overwrap-15mg-ml (Overwrap 15mg mL)
Label for Levetiracetam injection in 0.54% Sodium Chloride, 15 mg/mL strength, provided as 1500 mg per 100 mL single-dose bag for intravenous infusion. Manufactured for Baxter Healthcare Corporation, Deerfield, IL, made in Ireland. Label includes storage instructions and cautions for use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.